Another study developed a new algorithm dubbed IMPRES (IMmuno-PREdictive Score), which can predict response to anti-PD-1 and/or anti-CTLA-4 immune-checkpoint inhibitors in metastatic melanoma. Here, CTLA4 is linked to metastatic melanoma.